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ABSTRACT 
Objective: Lipid-based formulations have gained much attention, particularly on self-emulsifying drug delivery systems (SEDDS), to improve the 
oral bioavailability of lipophilic drugs. In the present study, an attempt was made to develop and evaluate prototype SEDDS of poorly soluble 
antiviral BCS class IV drug etravirine. 
Methods: Various oils, surfactants and co-surfactants were screened for their suitability in the formulation of SEDDS. Based on the screening, 
gelucire 44/14, as the oil, labrasol as a surfactant and transcutol HP as the co-surfactant were selected. SEDDS with drug etravirine was formulated 
and evaluated for emulsifying ability, dilution potential and microscopic properties. The emulsion area for each of the combination of oil and 
surfactant co-surfactant mixture (Smix) was determined by the construction of pseudo-ternary phase diagrams. 
Results: The optimized formulation with oil (gelucire 44/14) and Smix (labrasol: transcutol HP, 6:1) in a ratio of 2:8 exhibited a rapid emulsification 
rate and a good polydispersibility index of 0.103±0.012 indicating uniformity of the formed droplets. The size of the droplets was determined by 
zetasizer and was found to be in 200 nm range. The drug release from the final formulation after 2hr was found to be 41.15%±0.5 compared to 
19.3%±3.8 of pure drug indicating enhanced dissolution profile of the drug.  
Conclusion: In vitro study illustrated enhanced dissolution rate of formulated prototype SEDDS of BCS class IV drug etravirine for oral delivery. 
Keywords: Etravirine, SEDDS, Gelucire 44/1, BCS class IV, Labrasol, Transcutol 




Though management of HIV infection has been done successfully 
with antiviral drug therapy it is coupled with several limitations and 
inconveniences. The reason being most of the anti-retroviral drugs 
display poor oral bioavailability and a short half-life owing to poor 
aqueous solubility, extensive first-pass effect and gastrointestinal 
degradation. This invariably results in localized HIV in the certain 
inaccessible region of the body such as the CNS, the lymphatic 
system and macrophages [1, 2].  
FDA has approved etravirine a second generation Non-nucleoside 
reverse transcriptase inhibitors (NNRTI) for the treatment of HIV-1 
infection as it displays sustained virologic efficacy in a patient with 
NNRTI resistant HIV-1 infection. The drug undergoes extensive first-
pass metabolism as it is metabolized by hepatic cytochrome P450 
(CYP) 3A4 and other members of the CYP2C family. Etravirine is 
categorized under BCS class IV drug by virtue of its low aqueous 
solubility and permeability. It is highly lipophilic drug with log P 
value greater than 5 as it is nearly insoluble in water over a wide 
range of physiological pH [3-7].  
BCS class IV drugs are challenging molecule in product development 
as they exhibit low solubility and low permeability. However, 
formulation approaches similar to those for BCS class II drugs could 
be practically applied to BCS class IV drugs. Various approaches to 
overcome the poor aqueous solubility of drug candidates have been 
investigated and reported in the literature. In recent years, Lipid-
based formulations have been utilized to enhance the oral 
bioavailability of BCS class IV drugs and Self emulsifying drug 
delivery systems (SEDDS) is one among them [8-12].  
SEDDS are an isotropic mixture of oils, surfactants and co-
surfactants, which forms fine o/w emulsion upon dilution with the 
aqueous gastrointestinal medium on gentle agitation [13-16]. For 
lipophilic drug compounds exhibiting dissolution rate limited 
absorption, these systems offer an advantage to deliver lipophilic 
drugs to the systemic circulation, by avoiding the dissolution step 
(25). SEDDS improve the mucus permeation, rate and extent of 
absorption by facilitated intestinal lymphatic transport of drugs, as 
they are known to protect against enzymatic hydrolysis and inhibit 
P-gp efflux [17-19]. Some of the commercially successful antiviral 
SEDDS formulations are norvir (ritonavir) and Fortovase 
(saquinavir) generates (amprenavir), sustivas (efavirenz), and 
kaletras (lopinavir and ritonavir) [8].  
Based on extensive review of literature it is understood that there is 
not much work done on SEDDS of etravirine. Thus the current study 
was aimed to develop prototype SEDDS of etravirine and evaluate 
the emulsifying ability, microscopic property, stability and it's in 
vitro dissolution. 
MATERIALS AND METHODS 
Material 
Etravirine was obtained as a generous gift sample from Apotex 
Pharmachem INC (Bengaluru, India). Labrafil 2125 CS, peceol, 
gelucire 44/14, labrafac, lipophile WL 1349, lauroglycol-90, maisine-
35, labrasol and transcutol-HP are gift samples obtained from 
Gattefosse India (Mumbai, India). Captex 300 and captex 355 are 
gifted samples from Abitec Corporation (India). Tween 20, tween 60, 
span 20, span 80, PEG 200, PEG 400 were purchased from SD fine 
chemicals (Mumbai, India). Tri-Ester F-810 generous gift from India 
commercial company Private Ltd. Capmul MCM C8 L2p and captex 200 P 
are gifted samples from IMCD India private limited (Mumbai, India). All 
other chemicals and reagents were of analytical grade and procured 
from Merck (Mumbai, India) and SD Fine Chem. (Mumbai, India). 
Determination of solubility of etravirine in various vehicles  
The solubility of etravirine was determined in various oils, 
surfactants and co-surfactants by adding an excess amount of 
Etravirine in 1 ml of a pure vehicle taken in glass tubes and the 
mixture was heated at 60 °C in a water bath and vortexed 
intermittently to facilitate the solubilization. The drug suspension 
was equilibrated at 25 °C in a thermostatically controlled bath for 48 
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h. After equilibration, the tubes were centrifuged at 12,000 RPM for 
20 min and aliquots of the clear supernatants were further diluted 
with methanol or DMSO (based on the miscibility of the vehicle) and 
estimated for Etravirine by UV spectrophotometer at 317 nm for 
DMSO and 315 nm for methanol. 
Selection of surfactant  
The surfactants were screened based on their ability to emulsify the 
selected oil phase. To determine the emulsification ability, 20 μl of 
surfactant was mixed with 20 μl of the selected oily phase. Subsequently, 
25 μl of this mixture was diluted to 25 ml with distilled water. The 
number of inversions of volumetric flask required to produce a uniform 
emulsion was monitored. The emulsions were allowed to stand for 2 h 
and their transmittance was measured at 638.2 nm in UV-vis 
spectrophotometer against distilled water as the blank [20, 24].  
Selection of co-surfactant  
Co-surfactants were screened based on their efficacy to improve the 
emulsification ability of the selected surfactants. For this, 40 μl of 
selected surfactant was mixed with 20 μl of the co-surfactant (Smix 
ratio of 2:1). The selected oil was added to surfactant and co-
surfactant mixture in the ratio of 1:1 and gently heated in a water 
bath to allow proper mixing. 25 μl of this mixture was diluted to 25 
ml with distilled water and the ease of formation of emulsions was 
monitored by the number of inversions required to produce a 
uniform emulsion. The emulsions were allowed to stand for 2 h and 
their transmittance was measured at 638.2 nm in UV-vis spectro-
photometer against distilled water as the blank [20, 24]. 
Construction of a pseudo-ternary phase diagram  
A titration method was employed to construct phase diagrams. Various 
mixtures of the oil with surfactants or a combination of the surfactant 
and co-surfactant (Smix 2:1, 4:1, 6:1) was prepared at ratios of 10:0, 9:1, 
8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9, 0:10 into different vials. A small 
amount of water in 5% (w/w) increments were added into the vials and 
shaken for 15 min to 30 min at 25 °C. Addition of water is done till the 
mixture is diluted to a maximum of to 1000 times. After each increment 
of water different phases were observed: (1) a clear liquid region that 
included clear or translucent solutions; (2) cloudy liquids apparently 
consisting of coarse emulsions; (3) a viscous gel; or (4) a phase-
separated mixture where the lipid separated from the aqueous phase to 
form a separate layer [21, 24].  
Preparation of SEDDS 
Based on the solubility studies and Phase diagram, the oil (gelucire 
44/14), surfactant (labrasol) and co-surfactant (transcutol HP) were 
chosen for SEDDS formulations. A series of formulations were 
prepared using various concentrations (10-80% v/v) of oil, 
surfactant and co-surfactant. At first, the surfactant (labrasol) and 
co-surfactant (transcutol HP) were mixed in the ratio of 2:1, 4:1 and 
6:1 and a specific quantity of Smix as shown in table 1. The mixture 
obtained was mixed with gelucire 44/14 (oil) (which was previously 
heated at 45 °C for 5 min in a water bath) until a clear solution was 
obtained. Then, an excess amount of etravirine was added to the 
mixtures and mixed thoroughly. The formulations were shaken at 
ambient temperature for 48h and analyzed for etravirine content, as 
described above. 
 
Table 1: SEDDS formulations with various percentage oil, surfactant and co-surfactant 
Formulation O: Smix Smix Oil % Surfactant % Co-surfactant % 
F1 1:9 2:1 10 60 30 
F2 2:8  20 53.33 26.67 
F3 3:7  30 46.67 23.33 
F4 4:6  40 40 60 
F5 5:5  50 33.33 16.67 
F6 6:4  60 26.67 13.34 
F7 7:3  70 20 10 
F8 1:9 4:1 10 72 18 
F9 2:8  20 64 16 
F10 3:7  30 56 14 
F11 4:6  40 48 12 
F12 5:5  50 40 10 
F13 6:4  60 32 8 
F14 7:3  70 24 6 
F15 1:9 6:1 10 77.14 12.85 
F16 2:8  20 68.57 11.42 
F17 3:7  30 60 10 
F18 4:6  40 51.42 8.57 
F19 5:5  50 42.85 7.14 
F20 6:4  60 34.28 5.71 
F21 7:3  70 25.71 4.28 
 
Evaluation of SEDDS  
Percentage transmittance studies and self-emulsification 
assessment  
The self-emulsification of formulated SEDDS was evaluated using a 
standard USP XXII dissolution apparatus II. To carry out the study, a total 
of 0.1 ml of the SNEDDS formulation was mixed with 100 ml (1000 times 
dilution) of distilled water and gentle agitation was provided by rotating 
a standard stainless steel dissolution paddle at 50 RPM. Percentage 
transmittance was measured spectrophotometrically at 638.2 nm using 
water as a blank. The formulations were visually assessed for 
emulsification, precipitation and phase separation. [20, 22].  
Accelerated physical stability studies 
Centrifugation study  
The formulations were diluted 100 times with distilled water, 
centrifuged at 3500-5000 RPM for 30 min and then examined 
visually for any phase separation. Then the formulations were 
visually observed for instability such as phase separation, creaming 
or cracking. The formulations that were free from phase separation, 
creaming and cracking were chosen for the heating-cooling cycle.  
Heating and cooling cycle  
This study so designed involved six cycles between 4 °C and 40 °C 
with storage at each temperature for not less than 48 h. The 
formulations that did not show any sign of phase separation, 
creaming and cracking were considered as stable formulation.  
Attenuated total reflection-fourier transform infrared 
spectroscopy (ATR-FTIR) analysis  
To determine any interaction between the drug and any of the 
excipient used, ATR Spectra were recorded in the frequency range 
4000-400 wave numbers (cm-1) using FTIR-8400S, Shimadzu. 
Globule size analysis  
The droplet size distribution and polydispersity index (PDI) of the 
optimized SEDDS formulation were determined by Zetasizer Nano 
ZS, Malvern Instruments, UK. The formulation (0.1 ml) was added to 
Preethi et al. 
Int J App Pharm, Vol 10, Issue 2, 2018, 13-19 
 
15 
100 ml of water in a volumetric flask and mixed by inverting the 
flask for 4-5 times. Then a few ml aliquot was withdrawn and added 
into a sample cell for droplet size measurement. Each size value 
reported was the average of three independent measurements. 
Transmission electron microscopy (TEM) 
The morphology of the optimized SEDDS formulation was 
investigated using transmission electron microscope (Tecnai G2 
Spirit BioTwin) at an accelerated voltage of 120 KV. Briefly, a drop of 
diluted SNEDDS was placed on the grid. Approximately 2 min after 
sample deposition, the grid was tapped with filter paper to remove 
surface water and air-dried. The image was taken with transmission 
electron microscope at an acceleration voltage of 100 KV [20, 23]. 
In vitro drug release 
The in vitro drug release of selected SEDDS formulation was 
performed in a USP XXIII apparatus I. Hard gelatin capsule 
containing the formulation was rotated at 50 RPM in the dissolution 
vessel containing 900 ml of 0.01M HCl with 1% SLS in double 
distilled water as dissolution media maintained at 37 °C. A 1 ml of 
the aliquots was withdrawn at predetermined time intervals, (5, 15, 
30, 45 and 60 min) from the dissolution medium and replaced with 
fresh blank media. The withdrawn samples were filtered using 0.45 
mm Millipore filter and analyzed for drug content by UV-vis 
spectrophotometer (UV-1800, Shimadzu, Japan) using the 
corresponding blank medium at 317 nm [22, 23, 25]. 
RESULTS AND DISCUSSION  
Solubility study 
The SEDDS should have the good solvent capacity for the drug under 
investigation to achieve maximum drug loading in the final volume 
of SEDDS and should be a clear and monophasic liquid with good 
solvent capacity at ambient temperature when introduced to 
aqueous phase [26, 27]. The solubility of etravirine in various oils, 
surfactants and surfactants is shown in table 2. From the result, it is 
evident that etravirine exhibited the highest solubility in gelucire 
44/14 (110.3±10.01 mg/ml) that was selected as an oil phase for 
further investigation. Gelucire 44/14 is a medium chain lauroyl 
polyoxylglycerides official in european pharmacopoeia, which is a 
well-established excipient for solubility and bioavailability 
enhancement [28, 29]. Surfactants tween 20 (68.5 mg/ml), tween 60 
(56.9 mg/ml), tween 80 (52.13 mg/ml), cremophor EL (38.63 mg/ml) 
and cremophor RH60 (70.92 mg/ml) and co-surfactants PEG 200 
(59.98 mg/ml), PEG 400 (59.39±4.033) and transcutol HP (60.77 
mg/ml) were selected for further studies since etravirine solubility 
was greater than 50 mg except cremophor EL. 
 
Table 2: Solubility of etravirine in vehicles 
Oils/Vehicles Solubilitya in mg/ml 
Gelucire 44/14 110.3±10.01 
Captex 355 1.31±0.3748 
Captex 300 1.57±0.2524 
Tri Ester 1.36±0.4356 
Maisine 35-1 1.35±0.039 
Lauroglycol 90 2.4±0.201 
Labrafac 1.73±0.1068 
Tocopherol 3.32±0.7495 
Isopropyl Myristate 0.64±0.0056 
Oleic Acid 3.63±1.039 
Captex 200 4.44±0.1061 
Castor Oil 3.51±0.3111 
Peceol 5.87±1.980 
 Surfactants  
Tween 20 68.5±4.95 
Tween 60 56.9±14.94 
Tween 80 52.13±3.131 
Span 80 7.86±7.741 
Span 20 11.66±1.941 
Labrafac WL 1349 1.73±0.1068 
Caproyl PGMC 13.81±0.0707 
Labrasol 73.11±9.525 
Cremophor EL 38.63±7.092 
Cremophor RH 60 70.92±8.620 
C0-surfactants   
PEG 200 59.98±2.503 
PEG 400 59.39±4.033 
Capmul MCM 7.22±0.9051 
Transcutol HP 60.77±3.896 
Capmul MCM C8 13.8±0.0141 
aData expressed as mean±SD (n=3) 
 
Selection of surfactants 
Selection of surfactants in the formulation of SEDDS is crucial. The 
surfactants accepted for SEDDS should be safe, with relatively high 
hydrophilic-lipophilic balance (HLB) for the immediate formation of 
an emulsion or rapid spreading of the formulation and to solubilize 
high amount of lipophlic drug compounds. Generally, nonionic 
surfactants are preferred safer surfactants for oral ingestion since 
they impart stability to emulsion over a wider range of pH and ionic 
strength. Also, they facilitate absorption of the co-administered drug 
by making reversible changes in intestinal mucosal permeability [20, 
17]. In our studies selection of surfactants was done based on their 
emulsifying ability which is determined by measuring the % 
transmittance of the resulting emulsion [20]. All the selected 
surfactants showed good dispersing properties with greater 
transmittance value (table 3) which is attributed to higher HLB and 
hydrophilicity properties of surfactants [30]. 
Selection of the co-surfactant 
Nonionic surfactant reduces interfacial tension, increases the 
flexibility of the interfacial film and helps in the spontaneous 
emulsion formation [31]. It is selected based on the number of 
inversions required to produce emulsion and % transmittance of the 
dispersed emulsion. In comparison to PEG 200 and PEG 400 co-
surfactants, transcutol showed transmittance greater than 90% with 
all the selected surfactants. The combination of oil with selected 
surfactant and co-surfactant are reported in table 3. 
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Table 3: Emulsification efficiency with different surfactants and co-surfactants 
Surfactant HLB In %T  Co-surfactant 
Transcutol HP PEG 200  PEG 400 
In %T In %T In %T 
Tween 20 16.7 20 99.62 7 99.99 5 99.50 10 99.90 
Tween 60 14.9 35 99.35 13 100 5 100.00 13 100.00 
Tween 80 15 20 99.89 5 100 5 99.90 8 99.9 
Cremophor EL 12-14 20 89.99 5 100 6 99.92 9 99.92 
Cremophor RH60 15-17 15 99.40 17 100 5 100.00 5 100.00 
Labrasol 14 10 71.55 8 99.6 5 81.72 5 84.64 
In: Number of Inversion, %T: Percentage transmittance  
  
Construction of a pseudo-ternary phase diagram 
For a selection of surfactants forming wider emulsion region 
phase diagrams were constructed by the water titration method 
by mixing selected oil (gelucire 44/14) with different surfactants 
namely tween 20, tween 60, tween 80, cremophor EL, cremophor 
RH 60 and labrasol. As depicted in (fig. 1) labrasol showed wider 
emulsifying area with selected oil gelucire 44/14. Nonionic 
surfactant labrasol a saturated polyglycolysed C6-C14 glyceride 
has a good solubilizing capacity of a hydrophobic drug, and ability 
to emulsify and enhance intestinal absorption of the drug [32-35]. 
Hence labrasol was selected as surfactant and transcutol was 
selected as co-surfactant since it is reported to be a solubilizer and 
absorption promoter [36, 37].  
The ratio of surfactant to co-surfactant determines the emulsifying 
ability and plays an important role in the development of a stable 
emulsion by reducing interfacial energy and forming a barrier to 
coalescence [25]. Thus surfactant and co-surfactants were mixed in 
the ratio of 2:1, 4:1 and 6:1 for preparation of SEDDS. 
  
 
Fig. 1: Pseudo-ternary phase diagram of selected co-surfactant 
 
Table 4: Characterization and stability testing of SEDDS formulations 
Formulation 
SEDDS with drug 
% transmittance Stability after dilution 
 in Min 
 
Stability after 1 mo Centrifugation study Heating and cooling cycle  
F1 41.2 20 Clear Liquid   
F2 49.3 40 Clear Liquid stable stable 
F3 52.6 35 Clear Liquid stable stable 
F4 58.12 35 Clear Liquid stable stable 
F5 60.35 40 Translucent liquid stable stable 
F6 83.45 45 Phase separation -- -- 
F7 84.5 20 Phase separation -- - 
F8 54.7 30 Clear Liquid -- -- 
F9 65.5 45 Clear Liquid stable stable 
F10 70.3 35 Phase separation -- -- 
F11 76.8 60 Phase separation -- -- 
F12 84.51 50 Phase separation -- -- 
F13 91.59 40 Solidified -- -- 
F14 97.79 50 Phase separation -- -- 
F15 40.5 40 Clear liquid -- -- 
F16 60.1 40 Clear liquid stable stable 
F17 63.45 40 Phase separation -- -- 
F18 65.03 180 Solidified -- -- 
F19 67.99 180 Phase separation -- -- 
F20 77.32 40 Phase separation -- -- 
F21 94.98 30 Phase separation -- -- 
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Preparation and characterization of SEDDS  
A sequence of SEDDS loaded with 50 mg of drug were prepared 
using oil (gelucire 44/14) in the concentration range of 10% to 70% 
and mixed with Smix (labrasol: transcutol mix). Visual assessment of 
SEEDS formulations was done after one month for clarity, 
precipitation and phase separation. SEDDS containing 10-40% 
gelucire 44/14 was clear without precipitation and phase 
separation. SEDDS undergo gradual dilution in vivo to form an 
emulsion, so dilution test is done to find out phase separation and 
precipitation [38]. The SEDDS when diluted with water dispersed 
within 35 s to get non-turbid bluish white emulsion which indicated 
microemulsion formation [27] mainly due to higher HLB value of 
gelucire44/14 [33]. From dilution studies, it was observed that 6 
formulations F2, F3, F4, F5, F9 and F16 were stable for 2-3 h without 
precipitation, but the rest of the formulation precipitated within 30-
60 min resulting in decreased % transmittance. Results are depicted 
in table 4. The stability of the 6 formulations was tested by the 
centrifugation test after forming microemulsion and observed 
immediately. There was no phase separation and precipitation, 
indicating the stability of the microemulsion formed [20]. 
In vitro drug release  
The in vitro dissolution of etravirine from selected 6 SEDDS 
formulations was evaluated under sink conditions. Results are 
shown in the fig. 2. Pure drug showed 20% drug release in 2hr and 
all other 6 formulations released more than 80% of the drug in first 
5 min and decreased to 25% (F2), 32% (F3), 27% (F4), 30% (F5), 
39% (F9) and 41% (F16) at 2hr. the decrease in the percentage 
release can be ascribed to, precipitation of the drug form SEDDS. For 
the correlation between dissolution and time, DT50 was calculated, 
which is the time required to maintain the dissolution rate over 50% 
[39]. Formulation F16 showed maximum DT50 of 79 min compared 
to all other formulations and pure drug. Hence F16 was selected as 




Fig. 2: In vitro dissolution of selected SEDDS formulations 
 
Characterization of optimized formulation 
Optimized formulation F16 was analyzed for compatibility of the 
drug with excipients by ATR-FTIR. Spectra of drug confirms the 
presence of aromatic amine and amide stretching peak at 3300 cm1 
and 3500 cm1 and aromatic aryl stretching between 2220–2260 cm1. 
Blank SEDDS without drug showed main OH stretching at 3470 cm1, 
CH3 stretching peak at 2868 cm1 and C=O stretching at 1735 cm-1 
respectively which is due to triglycerides. Optimized SEDDS 
formulation F16 after one month showed overlapping of NH group 
of the drug with OH group of SEDDS vehicles and other peaks 
remained unchanged (fig. 3). Similar peaks were observed after 6 
mo indicating stability of the formulation. 
Transmission electron microscopic analysis was performed to 
investigate the morphology of the microemulsion after dilution. 
The droplet size analysis showed the quality of emulsion formed. 
The decrease in the droplet size reflects the formation of a better, 
close-packed film of the surfactant at the oil-water interface, 
thereby stabilizing the oil droplets [40]. The droplets size of F16 
emulsion was found to be within 200 nm with zeta potential 
of±36.8 mV, which indicates the submicron range with good 
stability after dilution [41]. Globule size and PDI of F16 
formulation were found to be 159 nm±0.156 and PDI of 
0.103±0.012, (fig. 4 and 5) which is a good indication of 
microemulsion formation with good PDI. 
 
 
Fig. 3: FTIR of drug and SEDDS formulation 
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Fig. 4: Average size, PDI and zeta potential of SEDDS formulation F16 
 
 
Fig. 5: TEM image of SEDDS formulation F16 
 
CONCLUSION  
Prototype SEDDS of etravirine was successfully formulated and 
investigated for its potential use for improving in vitro dissolution. 
Several SEDDS were prepared and evaluated for emulsification 
property and stability. The optimized SEDDS of etravirine showed 
enhanced dissolution rate compared to that of the pure drug with 
desired property of SEDDS. The added components in SEDDS, 
gelucire 44/14, labrasol and transcutol enhanced solubility and 
likely to enhance bioavailability by transporting the drug by 
transcellular route. Therefore SEDDS can be a viable formulation 
strategy for the oral delivery of etravirine. Further investigations are 
essential for confirming the potentiality of the etravirine self-
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